Geneva Capital Management LLC Purchases 206,202 Shares of Vericel Co. (NASDAQ:VCEL)

Geneva Capital Management LLC raised its position in Vericel Co. (NASDAQ:VCEL) by 43.6% in the 1st quarter, Holdings Channel.com reports. The firm owned 679,165 shares of the biotechnology company’s stock after buying an additional 206,202 shares during the period. Geneva Capital Management LLC’s holdings in Vericel were worth $35,330,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. MCF Advisors LLC increased its stake in shares of Vericel by 86.1% in the first quarter. MCF Advisors LLC now owns 482 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 223 shares during the period. Arcadia Investment Management Corp MI bought a new position in shares of Vericel during the first quarter valued at $27,000. DekaBank Deutsche Girozentrale bought a new position in shares of Vericel during the fourth quarter valued at $33,000. GAMMA Investing LLC acquired a new position in shares of Vericel during the fourth quarter worth $65,000. Finally, Sentry Investment Management LLC bought a new stake in shares of Vericel in the fourth quarter worth $136,000.

Vericel Price Performance

Shares of NASDAQ:VCEL traded up $3.96 during mid-day trading on Thursday, hitting $49.41. The company had a trading volume of 388,738 shares, compared to its average volume of 477,730. Vericel Co. has a one year low of $30.18 and a one year high of $53.05. The firm has a fifty day moving average price of $46.50 and a 200 day moving average price of $45.14. The company has a market capitalization of $2.40 billion, a PE ratio of -4,886.11 and a beta of 1.70.

Vericel (NASDAQ:VCEL) last announced its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.03. The firm had revenue of $51.28 million for the quarter, compared to analyst estimates of $49.07 million. Vericel had a net margin of 0.22% and a return on equity of 0.21%. The business’s quarterly revenue was up 25.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.16) earnings per share. Research analysts expect that Vericel Co. will post 0.11 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have commented on VCEL. Truist Financial reaffirmed a “buy” rating and set a $54.00 target price on shares of Vericel in a report on Tuesday, March 26th. StockNews.com raised Vericel from a “sell” rating to a “hold” rating in a research note on Friday, June 21st. HC Wainwright increased their target price on shares of Vericel from $53.00 to $55.00 and gave the company a “buy” rating in a research report on Thursday, May 9th. Finally, TD Cowen began coverage on shares of Vericel in a research report on Thursday, June 20th. They set a “buy” rating and a $55.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, Vericel has an average rating of “Moderate Buy” and an average target price of $48.17.

Insider Buying and Selling

In other Vericel news, insider Sean C. Flynn sold 1,474 shares of the firm’s stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $45.84, for a total value of $67,568.16. Following the completion of the sale, the insider now owns 487 shares of the company’s stock, valued at $22,324.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Vericel news, insider Sean C. Flynn sold 6,772 shares of Vericel stock in a transaction on Friday, June 21st. The shares were sold at an average price of $45.02, for a total transaction of $304,875.44. Following the transaction, the insider now directly owns 487 shares of the company’s stock, valued at approximately $21,924.74. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Sean C. Flynn sold 1,474 shares of the stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $45.84, for a total transaction of $67,568.16. Following the completion of the sale, the insider now owns 487 shares of the company’s stock, valued at approximately $22,324.08. The disclosure for this sale can be found here. In the last three months, insiders have sold 43,791 shares of company stock valued at $1,949,394. 7.20% of the stock is owned by company insiders.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.